Short Interest in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Declines By 36.7%

Posted by Geri Gentry on Jul 30th, 2026

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX – Get Free Report) was the recipient of a significant drop in short interest in July. As of July 15th, there was short interest totaling 3,594,821 shares, a drop of 36.7% from the June 30th total of 5,675,750 shares. Based on an average daily trading volume, of 1,809,105 shares, the short-interest ratio is currently 2.0 days. Currently, 6.8% of the shares of the stock are short sold.

Insiders Place Their Bets

In related news, CEO Todd C. Brady bought 250,000 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average price of $1.67 per share, with a total value of $417,500.00. Following the completion of the purchase, the chief executive officer owned 1,721,298 shares in the company, valued at $2,874,567.66. This represents a 16.99% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 11.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. 683 Capital Management LLC raised its position in shares of Aldeyra Therapeutics by 86.6% during the fourth quarter. 683 Capital Management LLC now owns 1,530,000 shares of the biotechnology company’s stock worth $7,925,000 after acquiring an additional 710,000 shares during the last quarter. CIBC Private Wealth Group LLC bought a new stake in Aldeyra Therapeutics in the third quarter valued at approximately $55,000. BNP Paribas Financial Markets increased its position in Aldeyra Therapeutics by 36.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,610 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 2,859 shares during the period. Global Retirement Partners LLC bought a new position in Aldeyra Therapeutics during the 4th quarter worth approximately $52,000. Finally, Bank of New York Mellon Corp raised its holdings in Aldeyra Therapeutics by 18.1% during the 1st quarter. Bank of New York Mellon Corp now owns 136,746 shares of the biotechnology company’s stock worth $231,000 after purchasing an additional 20,980 shares during the last quarter. 59.71% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Wall Street Zen raised Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Weiss Ratings downgraded Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 20th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Aldeyra Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $5.50.

View Our Latest Stock Report on Aldeyra Therapeutics

Aldeyra Therapeutics Price Performance

ALDX opened at $1.61 on Thursday. Aldeyra Therapeutics has a fifty-two week low of $1.07 and a fifty-two week high of $6.17. The company’s 50 day moving average price is $1.84 and its two-hundred day moving average price is $2.85. The firm has a market capitalization of $97.12 million, a price-to-earnings ratio of -3.50 and a beta of 1.16.

Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.07. As a group, equities research analysts predict that Aldeyra Therapeutics will post -0.43 EPS for the current year.

About Aldeyra Therapeutics

(Get Free Report)

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.